0
Missed or wrong diagnosis
0
Misdiagnosed cases in endometriosis and cervical cancer
NON-INVASIVE, TISSUE-BASED DIAGNOSTICS
HERA biotech
Diagnosing Endometriosis and Cervical Cancer—On Time. For Her.
As Seen In
THE PROBLEM--OUR SOLUTION
Disease Detection Shouldn’t Take Years
Hera delivers non-invasive, tissue-based diagnostics that replace guesswork with clarity, and delays with decisions that fit real-world care. Our AI-powered platform supports endometriosis detection and staging, along with point-of-care cervical diagnosis, integrated seamlessly into OB-GYN, fertility, and drug discovery workflows.
For patients, it means an end to years of dismissal—replaced by trust, relief, and confirmation they can finally act on.
For clinicians, it means faster decisions, built on deep science and tools designed for frontline care.
BY THE NUMBERS
Too Common to Be Ignored.
Too Delayed to Be Defended.
0
Women affected by endometriosis
0
Average endometriosis diagnostic delay
0
Annual cervical cancer diagnoses
0
Average cervical cancer diagnostic delay
The Diagnostic Blind Spot That Spans a Lifetime
Across two of the most prevalent and dangerous conditions in women’s health, the same story repeats:
Unheard symptoms, invasive diagnostic methods, poor accuracy, followup after followup. From missed windows to drastic intervention options, the diagnostic journeys for endometriosis and cervical cancer are slow, invasive, costly, and often miss the mark.
These conditions are underdiagnosed, underfunded, and devastating to quality of life.
Practice-Ready. Outcome-Driven.
Built to Lead AI-Powered Women's Health Diagnostics
Our tools exceed today’s standards and finally match the speed and accuracy patients deserve.
A non-invasive molecular test for endometriosis detection and staging, poised to replace the surgical gold standard.
0
Specificity
Results in days
A non-invasive, point-of-care cervical cancer diagnostic device for the detection of CIN2+ disease.
0
SENSIVITY
Real-time results
Fixing the Diagnostic Gap in Chronic Gynecologic Conditions
From conception to practice reality, Hera biotech is setting new standards in non-invasive diagnostics—backed by deep tech and big data, built for global adoption.
Clinician Demand Confirmed
MetriDx™ and HERAfem™ selected by top clinics in the space
Commercial Access Secured
HeraFem launching across Latin America in 2025, Asia and Africa in 2026
Intellectual Property Warranted
8 patents across molecular and physical methods of detection
Deep Tech and Big Data
14B data points, 1K+ samples, and 4 proprietary datasets powering early detection
Building What Diagnostics Should’ve Been From the Start
Built by Experts
25% of Hera’s investors are clinicians and doctoral-level experts, underscoring deep alignment between our platform and the physicians who use it.
Trusted by Clinicians
Science-based, clinically-tested. This isn’t just diagnostics reimagined. It’s biology, respected. Stay in the loop on clinical progress and investment opportunities.
Making Early Diagnosis Accessible
Access isn’t theoretical—it’s critical. Hera’s non-invasive diagnostics close that gap—deployable through point-of-care and lab workflows, cost-efficient and with reimbursement pathways already in motion.
Pioneering New Markets
Delivering biological truth in areas of the world troubled by inefficiencies and stigmas is a must. We’re restoring diagnostic opportunity worldwide - geographically, financially, and system-wide.